Regenxbio Inc (NASDAQ:RGNX) saw some unusual options trading activity on Monday. Stock investors purchased 2,330 call options on the stock. This is an increase of approximately 3,182% compared to the typical volume of 71 call options.

A number of research firms have recently weighed in on RGNX. ValuEngine downgraded shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. BidaskClub downgraded shares of Regenxbio from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Barclays raised their price target on shares of Regenxbio from $48.00 to $83.00 and gave the stock an “overweight” rating in a research report on Monday, August 13th. Raymond James set a $96.00 price target on shares of Regenxbio and gave the stock a “buy” rating in a research report on Thursday, November 8th. Finally, Bank of America raised their price target on shares of Regenxbio from $76.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 8th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $82.93.

In other news, insider Kenneth T. Mills sold 7,510 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $66.46, for a total transaction of $499,114.60. Following the completion of the sale, the insider now owns 348,530 shares of the company’s stock, valued at $23,163,303.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 18th. The stock was sold at an average price of $61.78, for a total transaction of $308,900.00. Following the sale, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at approximately $1,400,490.82. The disclosure for this sale can be found here. Insiders sold 334,467 shares of company stock valued at $21,805,087 in the last ninety days. 16.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP bought a new position in Regenxbio during the second quarter worth $14,712,000. Amalgamated Bank bought a new position in Regenxbio during the second quarter worth $332,000. RTW Investments LP lifted its stake in Regenxbio by 10.7% during the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after purchasing an additional 201,788 shares during the last quarter. Chicago Equity Partners LLC bought a new position in Regenxbio during the second quarter worth $3,195,000. Finally, Fred Alger Management Inc. bought a new position in Regenxbio during the second quarter worth $933,000. Hedge funds and other institutional investors own 75.92% of the company’s stock.

RGNX stock opened at $60.85 on Wednesday. Regenxbio has a twelve month low of $23.25 and a twelve month high of $85.10. The company has a market cap of $2.32 billion, a PE ratio of -24.84, a P/E/G ratio of 9.85 and a beta of -0.49.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.30. Regenxbio had a return on equity of 22.52% and a net margin of 44.30%. The firm had revenue of $5.31 million for the quarter. Research analysts expect that Regenxbio will post 2.16 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Regenxbio Sees Unusually High Options Volume (RGNX)” was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/11/20/regenxbio-sees-unusually-high-options-volume-rgnx.html.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: What is the float in trading stocks?

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.